NeoPrediX develops predictive analytics solutions for neonatal, maternal, and perinatal health. The company focuses on improving outcomes for newborns worldwide through innovative, evidence-based clinical technology. A recent investment from Springhood Ventures will accelerate the development and deployment of NeoPrediX’s solutions. NeoPrediX aims to scale its offerings to bring predictive tools to the neonatal community faster. The company and investor emphasize a shared mission of improving neonatal health globally. Springhood’s support is intended to help NeoPrediX navigate the journey from concept to impactful solutions. NeoPrediX is a University of Basel spin‑off that develops software to support medical staff in the early detection and treatment of perinatal and neonatal diseases and complications. Its tools aim to identify common newborn conditions — the article notes more than half of infants are affected by jaundice — and to flag cases that may progress to life‑threatening courses requiring timely intervention. Founded in 2020, the company operates from Basel and Regensburg and currently employs ten people. In a Series A financing NeoPrediX raised CHF 4.1 million. The proceeds will be used to further develop its medical early‑detection solutions so the prediction tools can recognize additional disease presentations and complications. CEO Thorsten Waloschek said the company's experienced and well‑capitalized investors will help with optimization and long‑term market establishment.

Total raised

$4M

Funding rounds

2

Latest round

Series A

Latest activity

Mar 2021